Informations générales (source: ClinicalTrials.gov)
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Interventional
Phase 3
Bristol-Myers Squibb (Voir sur ClinicalTrials)
février 2025
septembre 2031
29 mai 2025
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489
(Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus
Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy
in Participants with Extensive-Stage Small Cell Lung Cancer.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Christos Chouaid, Site 0047 | Contact (sur clinicalTrials) | |||
| CLCC INSTITUT CURIE | nicolas girard, Site 0050 | Contact (sur clinicalTrials) | |||
| CLCC INSTITUT GUSTAVE ROUSSY | Pernelle Lavaud, Site 0038 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Assistance Publique Hôpitaux de Marseille - Hôpital Nord - 13915 - Marseille - France | Laurent Greillier, Site 0043 | Contact (sur clinicalTrials) | |||
| Centre Hospitalier de Cornouaille Quimper - Concarneau - 29000 - Quimper - France | Romain Corre, Site 0215 | Contact (sur clinicalTrials) | |||
| Centre Hospitalier Lyon Sud - 69310 - Pierre-Bénite - Rhône - France | Sebastien Couraud, Site 0051 | Contact (sur clinicalTrials) | |||
| Chu Grenoble Alpes - 38700 - La Tronche - Isère - France | Denis Moro-Sibilot, Site 0040 | Contact (sur clinicalTrials) | |||
| CHU Lille - Institut Coeur Poumon - 59037 - Lille Cedex - Nord - France | Arnaud Scherpereel, Site 0052 | Contact (sur clinicalTrials) | |||
| Hôpital Arnaud de Villeneuve - CHU Montpellier - 34090 - Montpellier - Hérault - France | Benoit Roch, Site 0048 | Contact (sur clinicalTrials) | |||
| L Hopital Nord Ouest - 69400 - Gleize - Rhône - France | LIONEL FALCHERO, Site 0044 | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer
(ES-SCLC).
- Participants must be Healthy enough to do their normal activities with little or no
help based on the ECOG performance scale.
- Participants must have at least one tumor that can be measured using special imaging
techniques like a CT scan or MRI at a site other than the brain and nervous system
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer
(ES-SCLC).
- Participants must be Healthy enough to do their normal activities with little or no
help based on the ECOG performance scale.
- Participants must have at least one tumor that can be measured using special imaging
techniques like a CT scan or MRI at a site other than the brain and nervous system
- Participants have already received certain types of treatment for extensive stage
small cell lung cancer
- Participants have certain health conditions, like spread of small cell lung cancer
to the brain that are causing symptoms, certain lung diseases, heart diseases,
infections, autoimmune diseases, other cancers, or a type of nerve damage called
peripheral sensory neuropathy
- Other protocol-defined Inclusion/Exclusion criteria apply.